BIONEWS
Fifteen years after the first CAR-T, China cleared the first version for solid tumors
CAR T is an engineered immune cell therapy that treats blood cancers by reprogramming a patient's own immune cells.
CAR T is an engineered immune cell therapy that treats blood cancers by reprogramming a patient's own immune cells.
After fifteen years of engineered immune-cell therapies limited to blood cancers, China's National Medical Products Administration on June 22 approved the first CAR-T therapy that attacks solid tumors, with a Shanghai-based biotech reaching a clinical milestone that the U.S. academic labs that invented the field had not yet crossed.
The drug, satricabtagene autoleucel (satri-cel), was developed by CARsgen Therapeutics and targets Claudin18.2, a surface protein that stomach and gastroesophageal-junction tumors tend to express. China's regulator cleared it for adults with advanced HER2-negative, Claudin18.2-positive gastric or gastroesophageal-junction adenocarcinoma who have already been heavily treated, according to the company and trade press.
The approval rests on CT041-ST-01, a randomized, open-label phase 2 trial that compared satri-cel against treatment of physician's choice in previously treated Claudin18.2-positive advanced gastric and gastroesophageal-junction cancer, published in The Lancet00860-8/abstract). The study design matters: rather than relying on a single-arm response-rate benchmark, it pitted the engineered cells against whatever chemotherapy or targeted regimen each patient's doctor would otherwise pick. That comparator arm was the regulator's bet that satri-cel produces a meaningful comparative benefit, not just tumor shrinkage.
CAR-T, or chimeric antigen receptor T-cell therapy, takes a patient's own T cells, engineers them to recognize a specific protein on the surface of cancer cells, and infuses them back to hunt. The first clinical use came in 2010, and eight CAR-T medicines have reached market approval worldwide since, all of them for hematologic malignancies: leukemias, lymphomas, and multiple myeloma.
Solid tumors proved harder for three linked reasons. First, the antigens that circulating T cells naturally find in blood cancers (CD19, BCMA) are mostly absent on cells packed inside a tissue mass. Second, the microenvironment of a solid tumor is hostile to T-cell infiltration and persistence. Third, the safety margin is narrower: a CAR-T that kills a B cell leaves the patient temporarily immunocompromised but alive, while a CAR-T that kills a vital organ's surface protein can be fatal.
Claudin18.2 turned out to be an unusually workable target for the same reason it is clinically interesting. The protein is essentially restricted to the lining of the stomach, and it is overexpressed on a meaningful share of gastric and gastroesophageal-junction adenocarcinomas. Hit Claudin18.2 on a stomach tumor and you have a reasonable chance of clearing tumor cells before collateral damage becomes lethal, a problem that has bedeviled earlier attempts to target Claudin18.2 in pancreatic cancer, where the same protein appears at lower density.
CARsgen's construct is an autologous CAR-T (made from each patient's own cells) with a Claudin18.2-targeted single-chain variable fragment and a CD28-based costimulatory domain. Patients undergo leukapheresis, the engineered product is manufactured and infused after lymphodepleting chemotherapy, and the cells then circulate looking for Claudin18.2 on residual disease. The randomized comparison against physician's choice is what separates this approval from earlier single-arm signals in solid-tumor CAR-T: it gives regulators a real comparator arm rather than a historical benchmark.
BioWorld and Pharmaphorum both flagged the trial design and the regulatory pathway as the substantive pieces of the news, beyond the symbolic "first" label.
The U.S. field is not empty, but it is close, not there. Several U.S.-based programs have been pursuing Claudin18.2-targeted cell therapies and other solid-tumor CAR-T candidates, but none has yet produced a randomized pivotal readout in solid tumors comparable to CT041-ST-01. The practical effect is that any future U.S. filing in this class now has a hard randomized comparator to answer to.
What satri-cel changes is the bar. A Chinese approval grounded in a randomized phase 2 read-out against physician's choice, with the data published in The Lancet00860-8/abstract), gives the FDA a real-world regulatory precedent to evaluate rather than a single-arm signal. That precedent cuts both ways: if the durability and safety hold up in larger and longer follow-up, it lowers the evidentiary bar for Claudin18.2-targeted programs in the U.S.; if the readout ages poorly, it sharpens the questions the FDA will ask of the next round.
Three checkpoints matter. The first is whether CARsgen can file a Biologics License Application in the U.S. based on a bridging or confirmatory study, or whether an academic or industry partner will carry the program into an IND here. The second is whether the CT041-ST-01 durability, which the company has framed as clinically meaningful, holds up at 18- and 24-month follow-up in peer-reviewed updates. The third is whether other Claudin18.2 cell-therapy programs produce randomized pivotal data in the next two years.
The 15-year gap between the first CAR-T and the first solid-tumor CAR-T reflects a category, not a country. Stomach cancer is one of the leading causes of cancer death worldwide and disproportionately common in East Asia, and a new mechanism that works after chemotherapy has failed is a real clinical event, not a stock story. The surprise is that the first version was shipped from Shanghai, while the U.S. institutions that built the original CAR-T have not yet produced a solid-tumor version. The next eighteen months of clinical readouts will determine whether that lead holds or whether it compresses back to a one-approval race.